Evaluation of safety profiles of a Muse cell-based product, CL2020, in patients with ALS based on ALSFRS-R scores. (IMAGE)
Caption
The image above describes the changes in the mean scores for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) for ALS patients treated with CL2020. The arrowheads indicate the intravenous administration of CL2020 across six months. It was found that the change in ALSFRS-R scores trended upward over 12 months post-CL2020 treatment compared with 3 months pre-administration. This indicates that repeated CL2020 therapy is safe for ALS patients and has some positive therapeutic effect on certain ALS symptoms.
Credit
Toru Yamashita from Okayama University Graduate School of Medicine
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC